Opportunity Information: Apply for RFA DK 27 139
This funding opportunity is a National Institutes of Health (NIH) Notice of Funding Opportunity (NOFO) to support a 3-year extension or renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) consortium, specifically for the consortiums Scientific and Data Research Center (SDRC). The purpose of the extension is practical and completion-focused: it is meant to allow the ongoing COPE-AKI clinical trial effort to fully reach its enrollment goals, finish all required participant follow-up, and then complete final data management, statistical analyses, and publication and dissemination of results. In other words, this is not a call to launch a brand-new study; it is aimed at ensuring the existing, already-approved consortium trial can be completed rigorously and reported in a way that will be useful to clinicians and the broader kidney health community.
The NOFO emphasizes the clinical importance of the work by pointing out a key gap in current practice: there is no widely accepted standard of care for patients after they leave the hospital following an episode of acute kidney injury (AKI). AKI survivors, especially those with more severe Stage 2 or Stage 3 AKI, can face ongoing risks that may include recurrent kidney injury, progression toward chronic kidney disease, cardiovascular complications, rehospitalization, and other adverse outcomes. The COPE-AKI study is positioned as a way to generate evidence that can directly shape post-hospital clinical management strategies, with the longer-term goal of helping establish a clearer standard of care for these patients. The extension is therefore framed as essential to delivering the full scientific and clinical value of the trial, since incomplete enrollment or truncated follow-up would weaken the ability to draw reliable conclusions and translate findings into practice.
This is a single-source opportunity, meaning it is intentionally limited to one eligible applicant: the organization that already serves as the SDRC under the prior COPE-AKI award (referenced as RFA-DK-20-012). NIH is effectively signaling that continuity is required for this phase of work because the SDRC holds the established infrastructure, systems, and operational knowledge needed to manage trial data, coordinate scientific activities, and bring the study to completion. Even though the competition is limited, the application is still subject to NIH peer review under standard processes, and only an application judged to be scientifically and operationally meritorious would be considered for funding.
The award mechanism is a cooperative agreement (U01), which typically indicates substantial NIH programmatic involvement compared with a standard research project grant. In practice, this often means NIH staff may participate in oversight, coordination, and milestone-driven management alongside the awardee, which fits with the NOFOs focus on completing enrollment, ensuring high-quality follow-up, and finishing analysis and dissemination on schedule. The NOFO is categorized under Health and is listed under CFDA number 93.847, reflecting its placement within NIHs research funding portfolio.
Eligibility rules are narrow and explicit. Only the current SDRC award recipient from the earlier COPE-AKI funding announcement is eligible to apply. Foreign organizations are not eligible, non-U.S. components of U.S. organizations are not eligible, and foreign components (as NIH defines them in its Grants Policy Statement) are not allowed. These restrictions reinforce that the work is expected to be conducted within eligible U.S.-based institutional structures and that the continuation effort is designed for the existing domestic consortium framework.
Key administrative details provided include the funding opportunity number RFA-DK-27-139, an original application closing date of 2026-11-09, and an expectation of a single award. While an award ceiling is not stated in the provided summary, the overall intent is clear: fund one continuation SDRC for three years to complete the COPE-AKI trial and ensure the final results are analyzed and shared. The outcome NIH is aiming for is straightforward: a fully enrolled, fully followed, carefully analyzed clinical trial dataset that can support credible conclusions and practical guidance for improving care for Stage 2 and Stage 3 AKI survivors after hospitalization.Apply for RFA DK 27 139
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2026-08-31.
- Applicants must submit their applications by 2026-11-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQ)
What is this funding opportunity?
This is a National Institutes of Health (NIH) Notice of Funding Opportunity (NOFO) to support a 3-year extension or renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) consortium, specifically for the consortium's Scientific and Data Research Center (SDRC).
What is the main purpose of the 3-year extension?
The extension is intended to bring the ongoing COPE-AKI clinical trial effort to completion by enabling the project to (1) fully reach enrollment goals, (2) complete all required participant follow-up, and (3) finish final data management, statistical analyses, and publication and dissemination of results.
Is this NOFO intended to start a new study?
No. The opportunity is completion-focused and is not a call to launch a brand-new study. It is designed to ensure the existing, already-approved COPE-AKI consortium trial can be completed rigorously and reported in a way that is useful to clinicians and the kidney health community.
Why does NIH consider this work clinically important?
The NOFO highlights a gap in current practice: there is no widely accepted standard of care for patients after discharge from the hospital following an episode of acute kidney injury (AKI). The work is positioned to generate evidence that can shape post-hospital clinical management strategies and, over time, help establish a clearer standard of care.
Which patient population is specifically emphasized in the NOFO summary?
The summary emphasizes AKI survivors, particularly those who experienced more severe Stage 2 or Stage 3 AKI, who may face ongoing risks after hospitalization.
What risks for AKI survivors are mentioned as part of the rationale?
The summary notes that AKI survivors may be at risk for recurrent kidney injury, progression toward chronic kidney disease, cardiovascular complications, rehospitalization, and other adverse outcomes.
What outcomes is NIH aiming for by funding this extension?
NIH is aiming for a fully enrolled, fully followed, carefully analyzed clinical trial dataset that can support credible conclusions and practical guidance for improving care for Stage 2 and Stage 3 AKI survivors after hospitalization.
What part of the COPE-AKI consortium does this award support?
This NOFO specifically supports the consortium's Scientific and Data Research Center (SDRC), which is responsible for managing trial data, coordinating scientific activities, and supporting completion of analyses and dissemination.
Is this a competitive opportunity open to multiple applicants?
No. This is described as a single-source opportunity, meaning it is intentionally limited to one eligible applicant: the organization that already serves as the SDRC under the prior COPE-AKI award referenced as RFA-DK-20-012.
Why is it limited to a single source applicant?
The summary indicates NIH is requiring continuity because the existing SDRC holds the established infrastructure, systems, and operational knowledge needed to manage trial data, coordinate scientific activities, and complete the study.
Does peer review still apply even though it is single-source?
Yes. The application is still subject to NIH peer review under standard processes, and only an application judged to be scientifically and operationally meritorious would be considered for funding.
What is the award mechanism for this opportunity?
The award mechanism is a cooperative agreement (U01).
What does a cooperative agreement (U01) imply in this context?
The summary indicates a U01 typically involves substantial NIH programmatic involvement compared with a standard research project grant. In this case, it may include NIH participation in oversight, coordination, and milestone-driven management alongside the awardee to support on-schedule completion of enrollment, follow-up, analysis, and dissemination.
What is the funding opportunity number?
The funding opportunity number is RFA-DK-27-139.
What is the application closing date?
The original application closing date listed in the summary is 2026-11-09.
How many awards does NIH expect to make?
The summary states there is an expectation of a single award.
How long is the planned project period for this extension?
The extension is described as a 3-year extension or renewal for the SDRC to complete the COPE-AKI trial activities.
Is a maximum award amount (award ceiling) provided in the summary?
No. The provided summary does not state an award ceiling.
Which organizations are eligible to apply?
Eligibility is limited to the current SDRC award recipient from the earlier COPE-AKI funding announcement (referenced as RFA-DK-20-012). Only that organization is eligible to apply.
Are foreign organizations eligible to apply?
No. Foreign organizations are not eligible.
Are non-U.S. components of U.S. organizations allowed?
No. Non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The summary states that foreign components (as NIH defines them in its Grants Policy Statement) are not allowed.
What is the CFDA number listed for this opportunity?
The summary lists CFDA number 93.847.
What category is this opportunity listed under?
The NOFO is categorized under Health.
What would be the consequence of not completing enrollment or follow-up, according to the summary?
The summary indicates that incomplete enrollment or truncated follow-up would weaken the ability to draw reliable conclusions and translate findings into practice, which is why the extension is framed as essential.
What types of activities are explicitly called out as needing completion during the extension period?
The summary explicitly calls out completing enrollment, completing participant follow-up, final data management, statistical analyses, and publication and dissemination of results.
What prior COPE-AKI award is referenced for eligibility/continuity?
The summary references the earlier COPE-AKI funding announcement as RFA-DK-20-012, under which the current SDRC award recipient is identified as the only eligible applicant.
Browse more opportunities from the same category: Health
Previous opportunity: Enhancing Agricultural Opportunities for Military Veterans Competitive Grants Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 27 139
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 27 139) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 27 051 Funding Number: PAR 27 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 27 127 Funding Number: PAR 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) Apply for RFA CA 27 005 Funding Number: RFA CA 27 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 054 Funding Number: PAR 27 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 125 Funding Number: RFA DK 27 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) Apply for RFA AI 27 002 Funding Number: RFA AI 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Apply for PAR 27 056 Funding Number: PAR 27 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) Apply for PAR 27 112 Funding Number: PAR 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 27 068 Funding Number: PAR 27 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Long-term health outcomes of people living with spina bifida Apply for CDC RFA DD 26 0222 Funding Number: CDC RFA DD 26 0222 Agency: Centers for Disease Control - NCBDDD Category: Health Funding Amount: $300,000 |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) Apply for RFA AI 27 005 Funding Number: RFA AI 27 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional) Apply for PAR 27 076 Funding Number: PAR 27 076 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) Apply for RFA DK 27 112 Funding Number: RFA DK 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 27 053 Funding Number: PAR 27 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed) Apply for RFA AI 27 014 Funding Number: RFA AI 27 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Trauma Care Readiness and Coordination Cooperative Agreement Apply for EP U3R 26 002 Funding Number: EP U3R 26 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 002 Funding Number: RD ET RDA 26 002 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations Apply for CDC RFA DP 27 0023 Funding Number: CDC RFA DP 27 0023 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 27 139", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.